指南与共识重症综合管理与镇静镇痛

免疫治疗与分子治疗时代癌症患者的重症监护:SEOM-SEMICYUC的承诺

Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC.
指南 / 共识 · Med Intensiva (Engl Ed) · 2018-03-05
一句话结论SEOM与SEMICYUC于2017年签署协议,旨在改善合并危重并发症的癌症患者的重症监护质量,辅助决策、统一标准、减少主观性并建立沟通渠道。

癌症患者是暴露于癌症本身之外众多严重风险的脆弱群体。近年来,免疫治疗、靶向分子治疗、手术技术及支持治疗等进展使这些患者的预后大幅改善,同时因危重并发症入住ICU并接受重症医师监护的肿瘤患者生存期延长。因此有必要重新审视这些患者的重症监护支持,这带来了新的专业与组织挑战。SEOM与SEMICYUC于2017年签署协议,旨在改善合并危重并发症的癌症患者的医疗质量,该倡议寻求辅助决策、统一标准、减少主观性、建立沟通渠道,并深入探讨这些情况的伦理与科学层面。本文阐述促成该倡议的最重要原因。

要点

  • 癌症患者是暴露于癌症本身之外众多严重风险的脆弱群体。
  • 免疫治疗、靶向分子治疗、手术技术及支持治疗等进展使癌症患者预后大幅改善。
  • 因危重并发症入住ICU并接受重症医师监护的肿瘤患者生存期延长,需重新审视其重症监护支持。
  • SEOM与SEMICYUC于2017年签署协议,旨在改善合并危重并发症的癌症患者的医疗质量。
  • 该倡议寻求辅助决策、统一标准、减少主观性、建立沟通渠道,并深入探讨伦理与科学层面。

适用人群与场景

  • 合并危重并发症的癌症患者,入住ICU并接受重症医师监护。

研究设计与关键结果

  • 本文为SEOM-SEMICYUC共识文件,阐述促成2017年双方签署协议以改善合并危重并发症癌症患者医疗质量倡议的最重要原因。

证据类型、等级与局限

  • 证据类型:指南/共识(SEOM-SEMICYUC共识文件)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

指南或共识出处

  • SEOM-SEMICYUC共识文件:Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC,发表于Med Intensiva (Engl Ed)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Cancer patients are a vulnerable group exposed to numerous and serious risks beyond cancer itself. In recent years, the prognosis of these individuals has improved substantially thanks to several advances such as immunotherapy, targeted molecular therapies, surgical techniques, or developments in support treatment. This coincides with the prolonged survival of oncological patients admitted to the ICU due to critical complications, and under the supervision of intensivists. The time has therefore come to revisit the intensive care support of these patients, which poses new professional as well as organizational challenges. An agreement was signed in 2017 between the SEOM and SEMICYUC with the aim of improving the quality of care of cancer patients with critical complications. The initiative seeks to aid in decision-making, standardize criteria, decrease subjectivity, generate channels of communication, and delve deeper into the ethical and scientific aspects of these situations. This document sets forth the most important reasons that have led us to undertake this initiative.

来源:Med Intensiva (Engl Ed),查看原文。版权归原作者所有。

参考来源

  1. Carmona-Bayonas A, Gordo F, Beato C, et al. Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC. Med Intensiva (Engl Ed). 2018. PMID: 29519710. doi:10.1016/j.medin.2018.01.008

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。